Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072812 · ClinicalTrials.gov registry record · Phase 1
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
A Phase 1 study, sponsored by Annovis Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01072812 is a Phase 1 study that was terminated before completion, run by Annovis Bio. The registered enrollment target is 5 participants.
The verdict
NCT01072812, a Phase 1 study, was terminated before completion, sponsored by Annovis Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI. The effects of this treatment on biomarkers will also be determined in CSF, whole blood, and plasma or serum as primary pharmacodynamic (PD) objectives.
Interventions
- DRUG Posiphen® tartrate capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072812
The ClinicalTrials.gov registry entry for NCT01072812 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Posiphen® tartrate capsules is the first listed.
NCT01072812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072812 about?
NCT01072812 is a clinical study titled "Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment". This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI. The effects of this treatment on biomarkers will also be determined in CSF, whole blood, and plasma or serum as primary pharmacodynamic (PD...
What is the current status of trial NCT01072812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-02. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01072812?
The interventions under investigation include: Posiphen® tartrate capsules (DRUG).
Who is sponsoring clinical trial NCT01072812?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.